Company* |
Funding Institution |
Amount (M) |
Type |
Details (Date) |
Adenosine Therapeutics LLC* |
National Institute of Neurological Disorders and Stroke |
$0.137 |
Fast-track SBIR grant |
To fund additional research on the company's selective A2A adenosine receptor agonist, ATL-146e, for the prevention of injury due to spinal cord ischemia (3/11) |
Adenosine Therapeutics LLC* |
National Institute of Allergy and Infectious Diseases |
$1.04 |
Phase II SBTTR grant |
To continue development of A2A adenosine receptor agonists as an adjunct therapy for sepsis and sepsis syndrome (5/30) |
Affinium Pharmaceuticals* (Canada) |
Genome Canada and the Ontario Genomics Institute |
$7 |
Research grant |
For a program in viral proteomics (4/8) |
Altea Development Corp.* |
National Institute of Diabetes and Digestive and Kidney Diseases |
$0.944 |
Phase II SBIR grant |
To continue studies with Altea's MicroPor system for the non- invasive delivery of insulin (1/22) |
Anadys Pharmaceuticals Inc.* |
National Institutes of Health |
$0.225 |
Phase I SBIR grant |
For work on identifying novel antibiotics using structure-assisted drug design to discover and optimize small molecules that bind to and disrupt the function of the bacterial ribosome (2/25) |
Antigen Express Inc.* |
National Cancer Institute |
$0.292 |
Phase I SBIR grant |
To extend the development of a MHC Class II-based intratumoral gene therapy to produce an in vivo therapeutic cancer vaccine that elicits a helper T-cell anticancer response (4/29) |
Antigen Express Inc.* |
National Institute of Allergy and Infectious Diseases |
$0.3 |
Phase I SBIR grant |
To develop an Ii-key MHC Class II epitope-based vaccine to treat HIV (6/3) |
Aphios Corp.* |
National Cancer Institute |
ND |
Phase I SBIR grant |
To develop a natural pharmaceutical-grade (delta)9-THC product for medical use (6/4) |
Atox Bio* (Israel) |
U.S. Department of Defense |
$3.1 |
Research grant |
To develop and commercialize treatment that would prevent the deadly sequelae of toxic shock caused by Staphylococcal and Streptococcal bacteria, potential bioweapons (5/8***) |
Avanir Pharmaceuticals Inc. (AMEX:AVN) |
California Trade, Technology and Commerce Agency |
$0.15 |
California Technology Investment Partnership grant |
For defining and assessing the market for a genital herpes product using docosanol 10% cream (5/2) |
Avanir Pharmaceuticals Inc. (AMEX:AVN) |
National Institutes of Health |
$1 |
Phase II SBIR grant |
To develop a docosanol-based product as a topical treatment for reducing the severity and healing time of recurrent genital herpes infections (3/20) |
Biotica Technology Ltd. (UK) |
European Union |
€0.33 (US$0.29) |
Marie Curie Industry Host Fellowship grant |
To fund research for the design of polyketides for use as therapeutic substances and the development of new technologies for their production within micro-organisms (1/8) |
Biotica Technology Ltd.* (UK) |
Biotechnology and Biological Sciences Research Council |
$0.286 |
Small Business Research Initiative grant |
To fund research into new technologies that generate polyketides and peptides, and for their production within micro-organisms (4/8) |
Boston Biomedica Inc. (BBII) |
National Institutes of Health |
$0.7 |
Phase II SBIR grant |
For the use of its Pressure Cycling Technology to release DNA, RNA and proteins from cells and tissues, with particular emphasis on hard-to-lyse biomaterials (3/14) |
Cognia Corp.* |
National Institutes for General Medical Sciences |
$1 |
Phase II SBIR grant |
To further develop Cognia's protein database system, which is a curation and relational database system with graphic user interfaces that provide researchers with network and pathway builder tools, as well as advanced search algorithms (6/12) |
CombiMatrix Corp. (subsidiary of Acacia Research Corp.; ACRI) |
National Institutes of Health |
ND |
Phase I grant |
For the development of its protein biochip technology (2/20) |
Compugen Ltd. (Israel; CGEN) and DiagnoCure Inc. (Canada; TSE:CUR) |
Canada-Israel Industrial Research and Development Foundation |
C$0.8 (US$0.5) |
Grant |
To assist in the research and development of a nucleic acid probe-based diagnostic kit for the early detection of lung cancer (3/13) |
Consensus Pharmaceuticals Inc.* |
National Institute of Allergy and Infectious Diseases |
ND |
Phase I SBIR grant |
To advance its drug discovery program for CD4 receptor antagonists to prevent HIV from entering cells (4/16) |
Copernicus Therapeutics Inc.* |
Cystic Fibrosis Foundation |
$0.937 |
Development grant |
To advance the development of therapeutic treatments for cystic fibrosis (3/12) |
Copernicus Therapeutics Inc.* |
State of Ohio |
ND |
Technology Action Fund grant |
To fund optimization of aerosols of its nonviral compacted DNA nanoparticles for intrapulmonary delivery (6/20) |
CytoGenix Inc.* |
National Institutes of Health |
ND |
Phase I SBTTR grant |
To test the company's single-stranded DNA expression systems in a transgenic mouse model (3/26) |
Elitra Pharmaceuticals Inc.* |
Genome Canada and Genome Quebec |
C$5.74 (US$3.5) |
Research grant |
For Elitra's functional genomics efforts in Candida albicans and Aspergillus fumigatus (4/4) |
Galapagos Genomics NV* (Beligum) |
The Flemish Institute for the Promotion of Industrial Scientific-Technological Research and the Netherlands Institute for the Stimulation of Technological Development and Collaboration |
€4 (US$3.86) |
Technology development grant |
For a project to build libraries of specific human gene classes to discover therapeutic targets, and to develop an adenoviral-based knockdown technology applicable to in vitro and in vivo target discovery and validation (6/20) |
Icogen Corp.* |
National Institute of Allergy and Infectious Diseases |
ND |
SBIR grant |
To fund the first application of Icogen's new high-throughput GPCR activator screening technology (4/23) |
Illumina Inc. (ILMN) |
National Cancer Institute |
$1.2 |
Phase II research grant |
To develop an immunoassay system based on Illumina's BeadArray technology (3/12) |
Illumina Inc. (ILMN) |
National Institutes of Health |
$1 |
SBIR grant |
To further develop the company's Phase II studies in Bead-Array technology for parallel processing of array experiments (5/10) |
Indevus Pharmaceuticals Inc. (IDEV; formerly Interneuron Pharmaceuticals Inc., IPIC) |
UK's Department of International Development |
£16 (US$22.7) |
Research grant |
To test PRO 2000 and other vaginal microbicides designed to prevent HIV transmission; the grant supports a five-year program involving UK and African research groups (2/19) |
Introgen Therapeutics Inc. (INGN) |
National Cancer Institute |
$0.493 |
SBTTR grant |
To fund collaborative research between Introgen and Elizabeth Grimm, of the University of Texas M.D. Anderson Cancer Center, and to advance preclinical development of INGN 241 (1/22) |
Ixion Biotechnology Inc.* |
National Institutes of Health |
$0.099 |
SBIR grant |
To test a process that could trans-differentiate human bone marrow stem cells and mesenchymal stem cells into insulin producing islets (3/5) |
Ixion Biotechnology Inc.* |
National Institutes of Health |
$0.1 |
SBIR grant |
To test the hypothesis that liver stem cells can transdifferentiate into pancreatic endocrine cells, especially insulin-producing cells (6/21) |
Karo Bio USA Inc. (Sweden; SSE:KARO) |
Department of the Army |
ND |
Three-year grant |
For drug discovery in prostate cancer (3/12) |
Kosan Biosciences Inc. (KOSN) |
National Institute of Allergy and Infectious Diseases |
$0.23 |
Phase I SBIR grant |
To engineer Escherichia coli strains for improved production of polyketides (3/28) |
Kosan Biosciences Inc. (KOSN) |
National Institute of Standards and Technology |
$2 |
Advanced Technology Program grant |
To support fundamental research in the de novo assembly of polyketide synthases by combinatorial biosynthesis (6/12) |
Kosan Biosciences Inc. (KOSN) |
National Institutes of Health |
$0.1 |
Phase I SBIR grant |
To support its program to generate improved geldanamycin analogues to treat cancer (4/19) |
Kosan Biosciences Inc. (KOSN) |
National Institutes of Health |
$0.1 |
Phase I SBIR grant |
To support its program to generate epothilone analogues by partial chemical synthesis (5/8) |
Lexrite Labs Inc.* |
National Cancer Institute |
$0.5 |
Phase I SBIR grant |
To extend its antibody conjugate technology to develop new drugs capable of permanently binding to a selected tumor antigen on adenocarcinoma cells (4/15) |
LifeCell Corp. (LIFC) |
Office of Naval Research |
$0.824 |
Three-year grant |
To continue funding LifeCell's cell preservation program (2/21) |
Mendel Biotechnology Inc.* |
National Cancer Institute |
ND |
SBIR grant |
To fund research to discover naturally occurring plant genes that regulate the production of Taxol, a taxoid produced in the cells of yew trees (6/13) |
Mendel Biotechnology Inc.* |
U.S. Department of Agriculture |
ND |
SBIR grant |
To fund research to discover naturally occurring plant genes that regulate the production of natural rubber (5/21) |
Mixture Sciences Inc.* |
National Institutes of Health |
$0.6 |
Phase I SBIR grant |
To use its technology involving large combinatorial peptide libraries to identify and optimize peptide mimics of HIV-1 epitopes for use in the design of prophylactic vaccines for the treatment of HIV infections (1/17) |
Morewood Molecular Sciences Inc.* |
National Institutes of Health |
ND |
Phase I SBIR grant |
To support development of its high-throughput enzyme-assaying technology (5/20) |
Nonlinear Dynamics Ltd.* (UK) |
Department of Trade and Industry |
$0.63 |
Smart Exceptional Development award |
To fund a research-based project for the development of Progenera, a bioinformatics data engine with distributed computing technology to offer high-throughput data analysis management and mining solutions (4/18) |
Novasite Pharmaceuticals Inc. (subsidiary of Applied Molecular Evolution Inc.; AMEV) |
National Institutes of Health |
$2.4 |
Two-year grant |
To support the development of anti-obesity drug candidates (4/2) |
Novirio Pharmaceuticals Ltd.* |
European Commission |
€1.9 (US$1.64) |
Research grant |
To fund a research project titled “Flavitherapeutics“ (1/25) |
Ontogen Corp.* |
National Institutes of Health |
$1.3 |
Phase II SBIR grant |
For the development of enzyme inhibitors to aid in the regulation of blood glucose levels in people with Type II diabetes (1/8) |
Oxford BioMedica plc* (UK) |
USA Amyotrophic Lateral Sclerosis Association |
$0.12 |
Research grant |
To assess a series of five genes as components of a product to address the motor neuron disease market, of which Lou Gehrig's disease is the most common manifestation (6/25) |
Panacea Pharmaceuticals Inc.* |
National Institute of Aging |
ND |
Phase I SBIR grant |
To support research and development activities aimed at producing therapeutic drugs against the enzyme Human Aspartyl Beta-Hydroxylase (5/21) |
Panacos Pharmaceuticals Inc.* |
National Institute of Allergy and Infectious Disease |
$0.125 |
Phase I SBIR grant |
To support the preclinical development of PA-457, an inhibitor of HIV infection by a mechanism distinct from approved drugs (5/23) |
Paradigm Genetics Inc. (PDGM) and LION bioscience AG (Germany; LEON) |
National Institute of Standards and Technology |
$11.7 |
Advanced Technology Program grant |
To support the development of a target assessment technologies suite, which is intended to increase the number and success rate of validated targets for product development (6/11) |
Pharmasset Inc.* |
National Institutes of Health |
$0.1 |
Phase I SBTTR grant |
To fund research to develop nucleoside analogues cytotoxic only to Epstein-Barr virus thymidine kinase-expressing cells (1/7) |
Pharmos Corp. (PARS) |
Office of the Chief Scientist of Israel's Ministry of Industry and Trade |
$2.8 |
Development grant |
To help fund the development of dexanabinol for traumatic brain injury (6/6) |
Phase 2 Discovery Inc.* |
National Institute of Neurological Disorders and Stroke |
$1 |
Phase II SBIR grant |
To support the development of an early biomarker for predicting clinical outcome in patients with severe head injury (5/2) |
Phylos Inc.* |
National Institute of Allergy and Infectious Diseases |
ND |
Phase II SBIR grant |
To provide further funding over the next two years to develop a multiplex cytokine array using its Trinectin-binding proteins as capture and detection agents (6/17) |
Plexus Vaccine Inc.* |
Center for the Commercialization of Advanced Technologies |
ND |
Department of Defense grant |
To provide research and development funding that enables Plexus to acquire proof of concept for vaccine development for a biowarfare target (2/8) |
Prana Biotechnology Ltd. (Australia; PRNAF; ASX:PBT) |
Australian government |
ND |
Research grant |
To identify new peptides that cause degeneration in the brain (2/4) |
ProteoTech Inc.* |
National Institute of Aging |
$2.78 |
Research grants |
For programs designed to lead to therapeutics for the prevention and treatment of brain amyloid protein deposits present in patients with Alzheimer's disease (2/20) |
Psychiatric Genomics Inc.* |
National Institute of Child Health and Human Development |
$0.1 |
Phase I SBIR grant |
To support research to discover small-molecule nonpeptide agonists of the human secretin receptor for possible use in treating autism (5/29) |
Puresyn Inc.* |
National Institutes of Health |
$0.75 |
Phase II SBIR grant |
To support development of improved methods for purification of adeno-associatedviral vectors at scales suitable for production of gene therapies (6/21) |
Q3DM Inc.* |
National Institutes of Health |
$1.5 |
Phase II SBIR grant |
To further develop Q3DM's high-throughput, high-resolution cellular imaging systems (3/6) |
SIGA Technologies Inc. (SIGA) |
National Institutes of Health |
$0.865 |
Phase II SBIR grant |
To support the company's antibiotic development program at its research and development facility in Corvallis, Ore. (5/29) |
SignalGene Inc. (Canada; TSE:SGI) |
Genome Canada and Genome Quebec |
C$8.1 (US$5.1) |
Research grants |
SignalGene received the funding for a program focused on three disorders related to steroid hormones, namely osteoporosis, breast cancer and ovarian cancer (4/3) |
Southwest Foundation for Biomedical Research* |
National Institutes of Health |
$6.2 |
Five-year grant |
For advancing the medical community's understanding of antiprogestins; the foundation's senior scientist, Pemmaraju Rao, received the grant (4/16) |
The Biotechnology Institute* |
Wyeth Inc. |
$1 |
Challenge grant |
To support biotechnology education (6/13) |
TransMolecular Inc.* |
National Institutes of Health |
$0.76 |
Phase II SBIR grant |
To discover and develop pharmaceutical alternatives over the next two years for treating neuropathic pain (4/18) |
UK BioBank* |
Wellcome Trust, UK Medical Research Council and the UK Department of Health |
£45 (US$65.6) |
Research grant |
To collect DNA samples and health and lifestyle information from 500,000 volunteers; the samples will be held in public ownership for public benefit (4/29) |
Viragen Ltd. (Scotland; division of Viragen Inc.; AMEX:VRA) |
Scottish government |
$0.65 |
Development grant |
For the development of avian transgenic technology in collaboration with the Roslin Institute(5/16) |
Viscum AG* (Germany) |
German Research Ministry |
€2.55 (US$2.2) |
Four-year research grant |
For the development of cancer therapies based on fusion toxins (3/27***) |
Wyeth Vaccines (unit of Wyeth Pharmaceuticals; NYSE:WYE) |
National Institute of Allergy and Infectious Diseases |
$22.8 |
Research grant |
For five years to expand research on a vaccine shown to prevent an AIDS-like disease in monkeys (5/17) |
Xenerex Biosciences (subsidiary of Avanir Pharmaceuticals Inc.; AMEX:AVN) |
Center for Commercialization of Advanced Technology |
$0.075 |
Development grant |
To fund the initial development of a treatment that is intended to reduce the potentially damaging effects of exposure to anthrax toxins in humans (6/19) |
Xenon Genetics Research Inc.* (Canada) |
Genome Canada and Genome Quebec |
C$11 (US$6.9) |
Research grant |
To support two projects in genomics-based drug discovery (4/3) |
XenoPort Inc.* |
National Institutes of Health |
$0.145 |
Phase I SBIR grant |
To support development of new methods for identifying transcytosis pathways to be used in improving the oral absorption of certain drugs (4/10) |
TOTAL: $194.447M | ||||
Notes: | ||||
This chart does not include grants that are tied to agreements between biotech companies and non-profit institutions. | ||||
* Indicates a privately held company or institution. | ||||
** Unless otherwise indicated, symbols listed are on the Nasdaq market. | ||||
*** Denotes the date the item ran in BioWorld International. | ||||
ND = not disclosed; SBIR = Small Business Innovation Research; SBTTR = Small Business Technology Transfer Research | ||||
AMEX = American Stock Exchange; ASX = Australian Stock Exchange; NYSE = New York Stock Exchange; SSE = Stockholm Stock Exchange; TSE = Toronto Stock Exchange |